The extremely rapid increase in prostate cancer survival reflects the increase in diagnosis and treatment of asymptomatic prostatic cancers as a result of increasingly widespread use of prostate-specific antigen (PSA) tests during the 1990s (Evans and Møller, 2003). This evidence concerns the gene KLK3 and prostate cancer.